Labcorp forecasts upbeat annual profit on strong demand for diagnostic products

Labcorp, a leading laboratory services provider, announced on Tuesday that it expects annual profits to exceed Wall Street’s expectations, thanks to strong demand for its diagnostic tests. The company is banking on a steady increase in demand for non-urgent surgeries, particularly among older Americans, which has been driving growth in the past few quarters.

Labcorp, headquartered in North Carolina, anticipates a 5% to 6% growth in its diagnostic segment for the year 2026. The company projects its annual adjusted profit per share to range between $17.55 and $18.25, with the midpoint surpassing analysts’ average estimate of $17.50. CEO Adam Schechter expressed optimism about the company’s performance in 2026, emphasizing their focus on growth.

In terms of revenue, Labcorp expects to generate between $14.61 billion and $14.79 billion annually, slightly above analysts’ estimated $14.63 billion. Analyst Michael Cherny from Leerink Partners commended Labcorp’s strong performance, noting their ability to sustain growth in a robust market alongside competitor Quest Diagnostics.

Labcorp and Quest have both experienced growth in the past year due to agreements to manage hospital laboratories, which have expanded their market share. Labcorp’s fourth-quarter profits exceeded expectations, driven by continued demand in their diagnostics and central laboratory divisions. The company reported an adjusted profit of $4.07 per share for the quarter ending December 31, outperforming the estimated $3.94 per share.

Sales in Labcorp’s biopharma laboratory services segment, which provides research facilities for biopharmaceutical companies, increased by 3.4%, while the diagnostics business saw a 5.5% growth during the same period. Despite slightly lower than anticipated quarterly sales of $3.52 billion compared to the estimated $3.56 billion, Labcorp remains confident in its ability to maintain steady growth.

Overall, Labcorp is poised for a successful year ahead, fueled by strong demand for its services and a strategic focus on expansion and innovation. The company’s positive outlook aligns with industry trends and positions them as a key player in the competitive healthcare landscape.

This article was rewritten based on information provided by Reuters and edited for clarity and coherence.